"We delivered solid EPS growth while absorbing the impact of health care reform. Our priorities in 2011 are to make Prolia and XGEVA successes, advance and enrich our pipeline, and build value for our shareholders." Amgen's total product sales were $3,760 million in the fourth quarter of 2010 versus $ 3,743 million in the same period a year ago. U.S. product sales were $2,869 million in the fourth quarter of 2010 versus $2,882 million last year. Among the firm's major drugs, worldwide sales of Aransep decreased 2 percent while Epogen sales plunged 16 percent.